If you have atypical hemolytic uremic syndrome (aHUS) and are being treated with Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), you may wish to consider enrolling in OneSource, a complimentary and personalized patient support program by Alexion, the therapies’ manufacturer. What is aHUS? aHUS is a rare multi-organ disorder marked by the formation of excessive blood clots. These clots can block small blood vessels, particularly those in the kidneys. Mutations that affect proteins of the complement system…

You must be logged in to read/download the full post.